EMA rec­om­mends re­vok­ing au­tho­riza­tion of No­var­tis' sick­le cell drug

The Eu­ro­pean Med­i­cines Agency’s com­mit­tee for med­i­c­i­nal prod­ucts for hu­man use (CHMP) on Fri­day rec­om­mend­ed re­vok­ing the mar­ket­ing au­tho­riza­tion for No­var­tis’ treat­ment for a painful …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER